Regencell Bioscience Holdings (Regencell Bioscience Holdings) Cash-to-Debt : 24.98 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Regencell Bioscience Holdings's cash to debt ratio for the quarter that ended in Jun. 2023 was 24.98.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Regencell Bioscience Holdings could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Regencell Bioscience Holdings's Cash-to-Debt or its related term are showing as below:

RGC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.13 Max: 24.98
Current: 24.98

During the past 5 years, Regencell Bioscience Holdings's highest Cash to Debt Ratio was 24.98. The lowest was 0.02. And the median was 0.13.

RGC's Cash-to-Debt is ranked better than
83.21% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs RGC: 24.98

Regencell Bioscience Holdings Cash-to-Debt Historical Data

The historical data trend for Regencell Bioscience Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Regencell Bioscience Holdings Cash-to-Debt Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

0.12

0.13

0.02

21.29

24.98

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial				0.02	N/A	21.29	N/A	24.98

Competitive Comparison of Regencell Bioscience Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Cash-to-Debt falls into.

Regencell Bioscience Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Regencell Bioscience Holdings's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.565	/	(0.438	+	0.025)
	=	24.98

Regencell Bioscience Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.565	/	(0.438	+	0.025)
	=	24.98

Regencell Bioscience Holdings (NAS:RGC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Regencell Bioscience Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.